Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Summaries for Patients |21 March 2006

The Cost-Effectiveness of Preventive Strategies for Breast and Ovarian Cancer for Women with BRCA1 or BRCA2 Mutations

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information

  • The summary below is from the full report titled “Cost-Effectiveness of Preventive Strategies for Women with a BRCA1 or a BRCA2 Mutation.” It is in the 21 March 2006 issue of Annals of Internal Medicine (volume 144, pages 397-406). The authors are K. Anderson, J.S. Jacobson, D.F. Heitjan, J. Graff Zivin, D. Hershman, A.I. Neugut, and V.R. Grann.


Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians.
×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
  • FULL ARTICLE
    • What is the problem and what is known about it so far?
    • Why did the researchers do this particular study?
    • Who was studied?
    • How was the study done?
    • What did the researchers find?
    • What were the limitations of the study?
    • What are the implications of the study?
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link

What is the problem and what is known about it so far?

Mutations on breast cancer suppressor genes (BRCA1 and BRCA2) have been shown to increase the risk for breast and ovarian cancer. Genetic testing identifies women who might consider cancer screening or treatments to prevent developing cancer. However, not all women with one of these mutations will develop cancer, so identification of mutations may also needlessly expose women to unnecessary interventions to prevent cancer. Interventions to prevent cancer include oral contraceptives to reduce ovarian cancer risk, the drug tamoxifen to reduce breast cancer risk, and surgical removal of the ovaries (bilateral salpingo-oophorectomy) or the breasts (bilateral mastectomy). The balance among the costs, harms, and benefits of these various options is unclear.

Why did the researchers do this particular study?

To evaluate the costs, harms, and benefits of strategies that are currently available to women who have BRCA1 or BRCA2 mutations.

Who was studied?

Instead of studying actual patients, the researchers used a computer model to simulate what would happen to a virtual group of women with BRCA1 or BRCA2 mutations if they chose different preventive strategies.

How was the study done?

The researchers collected information about the risk for cancer in women with the mutations and their likely outcomes. They also collected information about the benefits, harms, and costs of 6 different strategies: oral contraceptives, tamoxifen, bilateral salpingo-oophorectomy, bilateral mastectomy, both surgeries, or surveillance. Surveillance meant careful follow-up with yearly mammography and breast examinations with breast ultrasonography, if needed, and gynecologic examinations with pelvic ultrasonography and blood tests every 6 months. The researchers used this information to develop a computer model that simulated what would happen to women with BRCA1 or BRCA2 mutations who chose each of the 6 options. The computer model considered costs, harms, and benefits in weighing the various options. The model also considered the value of certain outcomes over others. For example, the model assumed that women valued survival with their breasts intact higher than survival after mastectomy.

What did the researchers find?

Oophorectomy alone or with mastectomy resulted in the best balance between costs and benefits for 35-year-old women at high risk for cancer because of a BRCA mutation. The model showed that mastectomy becomes more favorable as women become older.

What were the limitations of the study?

These results depend on the accuracy of the computer model and may differ from what would happen in real life. In addition, how a particular woman values certain outcomes over others may differ from the values that the researchers used in their model.

What are the implications of the study?

Oophorectomy and oophorectomy with mastectomy seem to be the most cost-effective strategies to prevent breast and ovarian cancer in women at high risk for cancer because of BRCA1 or BRCA2 mutations. However, many factors will go into women's decisions about whether to have genetic testing and what to do if they have positive test results. It is hoped that this paper will help make policymakers and insurance companies more willing to pay for these preventive treatments when women want to have them.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

The Cost-Effectiveness of Preventive Strategies for Breast and Ovarian Cancer for Women with BRCA1 or BRCA2 Mutations. Ann Intern Med. 2006;144:I–40. doi: https://doi.org/10.7326/0003-4819-144-6-200603210-00002

Download citation file:

  • Ris (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2020

×
Permissions

Published: Ann Intern Med. 2006;144(6):I-40.

DOI: 10.7326/0003-4819-144-6-200603210-00002

©
2006 American College of Physicians
0 Citations
Advertisement

See Also
Cost-Effectiveness of Preventive Strategies for Women with a BRCA1 or a BRCA2 Mutation
View MoreView Less

Related Articles
Cost-Effectiveness of Preventive Strategies for Women with a BRCA1 or a BRCA2 Mutation
Annals of Internal Medicine; 144 (6): 397-406
Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation Statement
Annals of Internal Medicine; 143 (5): 355-361
Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: U.S. Preventive Services Task Force Recommendations
Annals of Internal Medicine; 143 (5): I-47
Taking Family History Seriously
Annals of Internal Medicine; 143 (5): 388-389
View MoreView Less

Journal Club
Review: Newer second-line drugs for diabetes are not more cost-effective than sulfonylureas
Annals of Internal Medicine; 168 (2): JC8
In treatment-resistant depression, adding cognitive–behavioral therapy to usual care was cost-effective at 1 y
Annals of Internal Medicine; 160 (12): JC13
Ivacaftor improved lung function in cystic fibrosis with G551D mutation
Annals of Internal Medicine; 156 (8): JC4-10
Annual screening with CA-125 and transvaginal ultrasonography did not reduce ovarian cancer incidence or mortality
Annals of Internal Medicine; 155 (6): JC3-8
View MoreView Less

Related Topics
Healthcare Delivery and Policy
Hematology/Oncology

Healthcare Delivery and Policy, Hematology/Oncology.

PubMed Articles
Hyperbaric oxygen treatment results in a group of Turkish central retinal artery occlusion patients with a combined presence of thrombophilic mutations.
Undersea Hyperb Med ;47(1):65-73.
Glucose Tolerance in Patients with Cystic Fibrosis - Results from the German Cystic Fibrosis Registry.
Klin Padiatr 2020.
View More

Results provided by: PubMed

Advertisement
CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Latest RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards and Cover

  • Personae (Cover Photo)
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2020 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×